Journal of Clinical Oncology, Vol 17, Issue 7
(July), 1999: 1983
© 1999 American Society for Clinical Oncology
Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
Timothy W. Jacobs,
Allen M. Gown,
Hadi Yaziji,
Melissa J. Barnes,
Stuart J. Schnitt
From the Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; and PhenoPath Laboratories and IRIS, Seattle, WA.
Address reprint requests to Stuart J. Schnitt, MD, Department of Pathology, Beth Israel Deaconess Medical Center–East Campus, 330 Brookline Ave, Boston, MA 02215; email sschnitt{at}caregroup harvard.edu.
ABSTRACT
PURPOSE: To evaluate the specificity of the HercepTest for Immunoenzymatic Staining (Dako Corp, Carpinteria, CA) for determining HER-2/neu protein expression in breast cancer.
MATERIALS AND METHODS: Forty-eight invasive breast cancers previously found to be HER-2/neu–negative by two different immunohistochemical (IHC) assays and not amplified for the HER-2/neu gene by fluorescence in situ hybridization were studied using the HercepTest kit. HercepTest was performed according to the manufacturer's guidelines, and the results were scored on a 0 to 3+ scale using the United States Food and Drug Administration (FDA)–approved grading system. In this system, cases scored as 2+ or 3+ are considered HER-2/neu–positive.
RESULTS: Among these 48 cases, the IHC score using the FDA-approved scoring system was 0 in four cases (8.3%), 1+ in 16 (33.3%), 2+ in 21 (43.8%), and 3+ in seven (14.6%). Therefore, 58.4% of these cases were categorized as HER-2/neu–positive, and the specificity of the HercepTest kit for HER-2/neu expression was 41.6%. However, with the use of a modified scoring system that took into account the level of staining of nonneoplastic epithelium, the specificity increased to 93.2%.
CONCLUSION: Our results indicate that the HercepTest kit, when used in accordance with the manufacturer's guidelines and the FDA-approved scoring system, results in a large proportion of breast cancers being categorized as positive for HER-2/neu protein expression and that many of these seem to be false-positives. Consideration of the level of staining of nonneoplastic epithelium resulted in improved specificity. The current FDA-approved scoring system for HercepTest results should be reevaluated before its widespread use in clinical practice.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J Zustin, K Boddin, M C Tsourlakis, E Burandt, M Mirlacher, F Jaenicke, J Izbicki, W Ruether, J M Rueger, C Bokemeyer, et al.
HER-2/neu analysis in breast cancer bone metastases
J. Clin. Pathol.,
June 1, 2009;
62(6):
542 - 546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al.
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Clin. Cancer Res.,
April 15, 2009;
15(8):
2895 - 2904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
J. Clin. Oncol.,
March 10, 2009;
27(8):
1323 - 1333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Di Leo, H. L. Gomez, Z. Aziz, Z. Zvirbule, J. Bines, M. C. Arbushites, S. F. Guerrera, M. Koehler, C. Oliva, S. H. Stein, et al.
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
J. Clin. Oncol.,
December 1, 2008;
26(34):
5544 - 5552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hayashi, M. Inokuchi, Y. Takagi, H. Yamada, K. Kojima, J. Kumagai, T. Kawano, and K. Sugihara
High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer
Clin. Cancer Res.,
December 1, 2008;
14(23):
7843 - 7849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-C. Bidard, M.-C. Matthieu, P. Chollet, I. Raoefils, C. Abrial, J. Domont, M. Spielmann, S. Delaloge, F. Andre, and F. Penault-Llorca
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
Ann. Onc.,
July 1, 2008;
19(7):
1261 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R A Walker, J M S Bartlett, M Dowsett, I O Ellis, A M Hanby, B Jasani, K Miller, and S E Pinder
HER2 testing in the UK: further update to recommendations
J. Clin. Pathol.,
July 1, 2008;
61(7):
818 - 824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Martin, A. Rodriguez-Lescure, A. Ruiz, E. Alba, L. Calvo, M. Ruiz-Borrego, B. Munarriz, C. A. Rodriguez, C. Crespo, E. de Alava, et al.
Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
J Natl Cancer Inst,
June 4, 2008;
100(11):
805 - 814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Di Palma, N Collins, M Bilous, A Sapino, M Mottolese, N Kapranos, F Schmitt, and J Isola
A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer
J. Clin. Pathol.,
June 1, 2008;
61(6):
757 - 760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yamada, Y. Ichikawa, S. Yamagishi, N. Momiyama, M. Ota, S. Fujii, K. Tanaka, S. Togo, S. Ohki, and H. Shimada
Amphiregulin Is a Promising Prognostic Marker for Liver Metastases of Colorectal Cancer
Clin. Cancer Res.,
April 15, 2008;
14(8):
2351 - 2356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ravaioli, F. Monti, M. M. Regan, F. Maffini, M. G. Mastropasqua, V. Spataro, M. Castiglione-Gertsch, I. Panzini, L. Gianni, A. Goldhirsch, et al.
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer
Ann. Onc.,
April 1, 2008;
19(4):
660 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Schwarz, M Rechenmacher, T Filbeck, R Knuechel, H Blaszyk, A Hartmann, and G Brockhoff
Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions
J. Clin. Pathol.,
March 1, 2008;
61(3):
272 - 277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-F. Huang, S.-K. Luo, J. Xu, J. Li, D.-R. Xu, L.-H. Wang, M. Yan, X.-R. Wang, X.-B. Wan, F.-M. Zheng, et al.
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia
Blood,
March 1, 2008;
111(5):
2854 - 2865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Viale, M. M. Regan, M. G. Mastropasqua, F. Maffini, E. Maiorano, M. Colleoni, K. N. Price, R. Golouh, T. Perin, R. W. Brown, et al.
Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
J Natl Cancer Inst,
February 6, 2008;
100(3):
207 - 212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cornolti, M. Ungari, M. L. Morassi, F. Facchetti, E. Rossi, D. Lombardi, and P. Nicolai
Amplification and Overexpression of HER2/neu Gene and HER2/neu Protein in Salivary Duct Carcinoma of the Parotid Gland
Arch Otolaryngol Head Neck Surg,
October 1, 2007;
133(10):
1031 - 1036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lee, W. C. Park, H. W. Yim, M. A. Lee, G. Park, and K. Y. Lee
Expression of c-erbB2, cyclin D1 and Estrogen Receptor and their Clinical Implications in the Invasive Ductal Carcinoma of the Breast
Jpn. J. Clin. Oncol.,
September 1, 2007;
37(9):
708 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mavi, T. F. Cermik, M. Urhan, H. Puskulcu, S. Basu, J. Q. Yu, H. Zhuang, B. Czerniecki, and A. Alavi
The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions
J. Nucl. Med.,
August 1, 2007;
48(8):
1266 - 1272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Verlinden, I. Vanden Bempt, G. Eelen, M. Drijkoningen, I. Verlinden, K. Marchal, C. De Wolf-Peeters, M.-R. Christiaens, L. Michiels, R. Bouillon, et al.
The E2F-Regulated Gene Chk1 Is Highly Expressed in Triple-Negative Estrogen Receptor /Progesterone Receptor /HER-2 Breast Carcinomas
Cancer Res.,
July 15, 2007;
67(14):
6574 - 6581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Hudis
Trastuzumab -- Mechanism of Action and Use in Clinical Practice
N. Engl. J. Med.,
July 5, 2007;
357(1):
39 - 51.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Valabrega, F Montemurro, and M Aglietta
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Ann. Onc.,
June 1, 2007;
18(6):
977 - 984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Barrett, H. Magee, D. O'Toole, S. Daly, and M. Jeffers
Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
J. Clin. Pathol.,
June 1, 2007;
60(6):
690 - 693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L Henriksen, B. B Rasmussen, A. E Lykkesfeldt, S. Moller, B. Ejlertsen, and H. T Mouridsen
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays
J. Clin. Pathol.,
April 1, 2007;
60(4):
397 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Dal Lago, V. Durbecq, C. Desmedt, R. Salgado, T. Verjat, L. Lespagnard, Y. Ma, I. Veys, A. Di Leo, C. Sotiriou, et al.
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
Mol. Cancer Ther.,
October 1, 2006;
5(10):
2572 - 2579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Banerjee, J S Reis-Filho, S Ashley, D Steele, A Ashworth, S R Lakhani, and I E Smith
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
J. Clin. Pathol.,
July 1, 2006;
59(7):
729 - 735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Henry and D. F. Hayes
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
Oncologist,
June 1, 2006;
11(6):
541 - 552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Lyall, S. R. Dundas, S. Curran, and G. I. Murray
Profiling Markers of Prognosis in Colorectal Cancer
Clin. Cancer Res.,
February 15, 2006;
12(4):
1184 - 1191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Vinatzer, B. Dampier, B. Streubel, M. Pacher, M. J. Seewald, C. Stratowa, K. Kaserer, and M. Schreiber
Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization
Clin. Cancer Res.,
December 1, 2005;
11(23):
8348 - 8357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Li-Ning-T, R. Ronchetti, C. Torres-Cabala, and M. J. Merino
Role of Chromogenic in Situ Hybridization (CISHTM) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish
International Journal of Surgical Pathology,
October 1, 2005;
13(4):
343 - 351.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Onn, D. H. Choe, R. S. Herbst, A. M. Correa, R. F. Munden, M. T. Truong, A. A. Vaporciyan, T. Isobe, M. Z. Gilcrease, and E. M. Marom
Tumor Cavitation in Stage I Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome
Radiology,
October 1, 2005;
237(1):
342 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Ainsworth, J M S Bartlett, J J Going, E A Mallon, A Forsyth, J Richmond, W Angerson, A Watters, and B Dunne
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma
J. Clin. Pathol.,
October 1, 2005;
58(10):
1086 - 1090.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Press, G. Sauter, L. Bernstein, I. E. Villalobos, M. Mirlacher, J.-Y. Zhou, R. Wardeh, Y.-T. Li, R. Guzman, Y. Ma, et al.
Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials
Clin. Cancer Res.,
September 15, 2005;
11(18):
6598 - 6607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Witkiewicz, S. Varambally, R. Shen, R. Mehra, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, M. A. Rubin, and C. G. Kleer
{alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis
Cancer Epidemiol. Biomarkers Prev.,
June 1, 2005;
14(6):
1418 - 1423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z-H Xian, S-H Zhang, W-M Cong, W-Q Wu, and M-C Wu
Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma
J. Clin. Pathol.,
May 1, 2005;
58(5):
500 - 503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Kim, G. Ishii, K. Goto, K. Nagai, K. Tsuta, S. Shiono, J. Nitadori, T. Kodama, Y. Nishiwaki, and A. Ochiai
Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung
Clin. Cancer Res.,
November 1, 2004;
10(21):
7311 - 7317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yaziji, T. S. Barry, and A. M. Gown
HER-2 Testing in Breast Cancer--Reply
JAMA,
October 20, 2004;
292(15):
1818 - 1818.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Tubbs and D. G. Hicks
HER-2 Testing in Breast Cancer
JAMA,
October 20, 2004;
292(15):
1817 - 1818.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Arpino, S. J. Green, D. C. Allred, D. Lew, S. Martino, C. K. Osborne, and R. M. Elledge
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study
Clin. Cancer Res.,
September 1, 2004;
10(17):
5670 - 5676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi
Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial
Clin. Cancer Res.,
July 15, 2004;
10(14):
4639 - 4644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Isola, M. Tanner, A. Forsyth, T. G. Cooke, A. D. Watters, and J. M. S. Bartlett
Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization
Clin. Cancer Res.,
July 15, 2004;
10(14):
4793 - 4798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yaziji, L. C. Goldstein, T. S. Barry, R. Werling, H. Hwang, G. K. Ellis, J. R. Gralow, R. B. Livingston, and A. M. Gown
HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
JAMA,
April 28, 2004;
291(16):
1972 - 1977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Wiley and L. K. Diaz
High-Quality HER-2 Testing: Setting a Standard for Oncologic Biomarker Assessment
JAMA,
April 28, 2004;
291(16):
2019 - 2020.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K. Diaz, R. Gupta, N. Kidwai, N. Sneige, and E. L. Wiley
The Use of TMA for Interlaboratory Validation of FISH Testing for Detection of HER2 Gene Amplification in Breast Cancer
J. Histochem. Cytochem.,
April 1, 2004;
52(4):
501 - 507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
J. Clin. Oncol.,
March 1, 2004;
22(5):
854 - 863.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Onn, A. M. Correa, M. Gilcrease, T. Isobe, E. Massarelli, C. D. Bucana, M. S. O'Reilly, W. K. Hong, I. J. Fidler, J. B. Putnam, et al.
Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer
Clin. Cancer Res.,
January 1, 2004;
10(1):
136 - 143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nahta and F. J. Esteva
HER-2-Targeted Therapy: Lessons Learned and Future Directions
Clin. Cancer Res.,
November 1, 2003;
9(14):
5078 - 5084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Heinmoller, C. Gross, K. Beyser, C. Schmidtgen, G. Maass, M. Pedrocchi, and J. Ruschoff
HER2 Status in Non-Small Cell Lung Cancer: Results from Patient Screening for Enrollment to a Phase II Study of Herceptin
Clin. Cancer Res.,
November 1, 2003;
9(14):
5238 - 5243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Janicke, L. Mauriac, E. Quebe-Fehling, H. A. Chaudri-Ross, D. B. Evans, et al.
Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status
Cancer Res.,
October 1, 2003;
63(19):
6523 - 6531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pellegrini, M. Falleni, A. Marchetti, B. Cassani, M. Miozzo, F. Buttitta, M. Roncalli, G. Coggi, and S. Bosari
HER-2/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluorescence in Situ Hybridization, and Immunohistochemistry
Clin. Cancer Res.,
September 1, 2003;
9(10):
3645 - 3652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Lal, P. A. Salazar, M. Ladanyi, and B. Chen
Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification
J. Mol. Diagn.,
August 1, 2003;
5(3):
155 - 159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Decensi, C. Robertson, G. Viale, F. Pigatto, H. Johansson, E. R. Kisanga, P. Veronesi, R. Torrisi, M. Cazzaniga, S. Mora, et al.
A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers
J Natl Cancer Inst,
June 4, 2003;
95(11):
779 - 790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Brey, Z. Lalani, C. Johnston, M. Wong, L. V. McIntire, P. J. Duke, and C. W. Patrick Jr.
Automated Selection of DAB-labeled Tissue for Immunohistochemical Quantification
J. Histochem. Cytochem.,
May 1, 2003;
51(5):
575 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Burstein, L. N. Harris, R. Gelman, S. C. Lester, R. A. Nunes, C. M. Kaelin, L. M. Parker, L. W. Ellisen, I. Kuter, M. A. Gadd, et al.
Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study
J. Clin. Oncol.,
January 1, 2003;
21(1):
46 - 53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Di Lorenzo, G. Tortora, F. P. D'Armiento, G. De Rosa, S. Staibano, R. Autorino, M. D'Armiento, M. De Laurentiis, S. De Placido, G. Catalano, et al.
Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer
Clin. Cancer Res.,
November 1, 2002;
8(11):
3438 - 3444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Bernard and C. T. Wittwer
Real-Time PCR Technology for Cancer Diagnostics
Clin. Chem.,
August 1, 2002;
48(8):
1178 - 1185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein
Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens
J. Clin. Oncol.,
July 15, 2002;
20(14):
3095 - 3105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. K. Funkhouser and K. Kaiser-Rogers
Significance of, and Optimal Screening for, HER-2 Gene Amplification and Protein Overexpression in Breast Carcinoma
Ann. Clin. Lab. Sci.,
October 1, 2001;
31(4):
349 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Pritchard
Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?
J. Clin. Oncol.,
September 15, 2001;
19(18):
3795 - 3797.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Ellis, A. Coop, B. Singh, L. Mauriac, A. Llombert-Cussac, F. Janicke, W. R. Miller, D. B. Evans, M. Dugan, C. Brady, et al.
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1- and/or ErbB-2-Positive, Estrogen Receptor-Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
J. Clin. Oncol.,
September 15, 2001;
19(18):
3808 - 3816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Osman, H. I. Scher, M. Drobnjak, D. Verbel, M. Morris, D. Agus, J. S. Ross, and C. Cordon-Cardo
HER-2/neu (p185neu) Protein Expression in the Natural or Treated History of Prostate Cancer
Clin. Cancer Res.,
September 1, 2001;
7(9):
2643 - 2647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Brabender, K. D. Danenberg, R. Metzger, P. M. Schneider, J. Park, D. Salonga, A. H. Holscher, and P. V. Danenberg
Epidermal Growth Factor Receptor and HER2-neu mRNA Expression in Non-Small Cell Lung Cancer Is Correlated with Survival
Clin. Cancer Res.,
July 1, 2001;
7(7):
1850 - 1855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Birner, G. Oberhuber, J. Stani, C. Reithofer, H. Samonigg, H. Hausmaninger, E. Kubista, W. Kwasny, D. Kandioler-Eckersberger, M. Gnant, et al.
Evaluation of the United States Food and Drug Administration-approved Scoring and Test System of HER-2 Protein Expression in Breast Cancer
Clin. Cancer Res.,
June 1, 2001;
7(6):
1669 - 1675.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Seidman, M. N. Fornier, F. J. Esteva, L. Tan, S. Kaptain, A. Bach, K. S. Panageas, C. Arroyo, V. Valero, V. Currie, et al.
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
J. Clin. Oncol.,
May 15, 2001;
19(10):
2587 - 2595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, and T.M. Grogan
Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message
J. Clin. Oncol.,
May 15, 2001;
19(10):
2714 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Burstein, I. Kuter, S. M. Campos, R. S. Gelman, L. Tribou, L. M. Parker, J. Manola, J. Younger, U. Matulonis, C. A. Bunnell, et al.
Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer
J. Clin. Oncol.,
May 15, 2001;
19(10):
2722 - 2730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yamauchi, V. Stearns, and D. F. Hayes
When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer
J. Clin. Oncol.,
April 15, 2001;
19(8):
2334 - 2356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. N. Harris, V. Liotcheva, G. Broadwater, M. J. Ramirez, P. Maimonis, S. Anderson, T. Everett, D. Harpole, M. B. Moore, D. A. Berry, et al.
Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy
J. Clin. Oncol.,
March 15, 2001;
19(6):
1698 - 1706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lebeau, D. Deimling, C. Kaltz, A. Sendelhofert, A. Iff, B. Luthardt, M. Untch, and U. Lohrs
HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization
J. Clin. Oncol.,
January 15, 2001;
19(2):
354 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Signoretti, R. Montironi, J. Manola, A. Altimari, C. Tam, G. Bubley, S. Balk, G. Thomas, I. Kaplan, L. Hlatky, et al.
Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
J Natl Cancer Inst,
December 6, 2000;
92(23):
1918 - 1925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Pauletti, S. Dandekar, H. Rong, L. Ramos, H. Peng, R. Seshadri, and D. J. Slamon
Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry
J. Clin. Oncol.,
November 1, 2000;
18(21):
3651 - 3664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tanner, D. Gancberg, A. Di Leo, D. Larsimont, G. Rouas, M. J. Piccart, and J. Isola
Chromogenic in Situ Hybridization : A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer Samples
Am. J. Pathol.,
November 1, 2000;
157(5):
1467 - 1472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Tubbs, J. Pettay, P. Roche, M. H. Stoler, R. Jenkins, J. Myles, and T. Grogan
Concomitant Oncoprotein Detection with Fluorescence in Situ Hybridization (CODFISH): A Fluorescence-Based Assay Enabling Simultaneous Visualization of Gene Amplification and Encoded Protein Expression
J. Mol. Diagn.,
May 1, 2000;
2(2):
78 - 83.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S Wang, M H Saboorian, E Frenkel, L Hynan, S T Gokaslan, and R Ashfaq
Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
J. Clin. Pathol.,
May 1, 2000;
53(5):
374 - 381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Seelig, T. W. Jacobs, S. J. Schnitt, A. M. Gown, and H. Yaziji
Fluorescence In Situ Hybridization Versus Immunohistochemistry: Importance of Clinical Outcome
J. Clin. Oncol.,
November 1, 1999;
17(11):
3690 - 3692.
[Full Text]
[PDF]
|
|
|
|
